Compounders Research Compare

Gossamer Bio, Inc.(GOSS)

Biotechnology · San Diego, CA

$10.65-0.06 (-0.56%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Gossamer Bio, Inc.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

San Diego, CA

162 employees

www.gossamerbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Faheem Hasnain

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T13:26:41.194Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:26:41.194Z.

Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 65,077,720
Total debt · period ending 2026-06-30: 39,103,000
Cash · period ending 2026-06-30: 41,148,000
TTM operating EBITDA · period ending 2026-06-30: -165,377,000

FMP input reference: b98ba4015092d5f9d3a8f7230bb6a5b98cf1bb4c669b9b66f04bb37649ead8fd

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GOSS EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

GOSS Competitors' EV/EBITDA Ratio

Gossamer Bio, Inc.

Current

Market Cap

$65.08M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

InterCure Ltd.

Market Cap

$64.56M

EV/EBITDA Ratio

N/A

TTM Avg

7.83x

3Y Avg

18.88x

5Y Avg

17.80x

Cingulate Inc.

Market Cap

$63.98M

EV/EBITDA Ratio

0.21x

TTM Avg

0.03x

3Y Avg

0.03x

5Y Avg

0.03x

Alps Group Inc

Market Cap

$66.56M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PDS Biotechnology Corporation

Market Cap

$67.11M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kalaris Therapeutics Inc

Market Cap

$61.77M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Champions Oncology, Inc.

Market Cap

$69.05M

EV/EBITDA Ratio

260.01x

TTM Avg

103.53x

3Y Avg

75.29x

5Y Avg

64.49x

MiNK Therapeutics, Inc.

Market Cap

$60.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Fortress Biotech, Inc.

Market Cap

$69.43M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Adicet Bio, Inc.

Market Cap

$60.48M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Gossamer Bio, Inc. (GOSS)	$65.08M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$64.56M	N/A	7.83x	18.88x	17.80x
Cingulate Inc. (CING)vs ›	$63.98M	0.21x	0.03x	0.03x	0.03x
Alps Group Inc (ALPS)vs ›	$66.56M	N/A	N/A	N/A	N/A
PDS Biotechnology Corporation (PDSB)vs ›	$67.11M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$61.77M	N/A	N/A	N/A	N/A
Champions Oncology, Inc. (CSBR)vs ›	$69.05M	260.01x	103.53x	75.29x	64.49x
MiNK Therapeutics, Inc. (INKT)vs ›	$60.78M	N/A	N/A	N/A	N/A
Fortress Biotech, Inc. (FBIO)vs ›	$69.43M	N/A	N/A	N/A	N/A
Adicet Bio, Inc. (ACET)vs ›	$60.48M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics